Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Neoplasm Metastasis 2Endometrial Neoplasms 2Breast Neoplasms 2Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Prostatic Diseases 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Male Urogenital Diseases 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Genital Diseases, Male 1

Interventions

pembrolizumab 105Specimen Handling 55Magnetic Resonance Spectroscopy 48Biopsy 47Nivolumab 40Paclitaxel 35Gemcitabine 30Radiosurgery 29Carboplatin 28Irinotecan 22Ipilimumab 22Cyclophosphamide 22Cisplatin 22trastuzumab deruxtecan 21Leucovorin 19Capecitabine 19Fluorouracil 18Cetuximab 18Bevacizumab 18130-nm albumin-bound paclitaxel 18Pemetrexed 17Fulvestrant 17Drug Therapy 16Docetaxel 16Taxes 15Oxaliplatin 15olaparib 14abemaciclib 14Radiotherapy 14palbociclib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × gedatolisib × 1 year × Clear all
NCT06757634 2026-05-18

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Celcuity Inc

Phase 3 Recruiting
1,180 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05501886 2026-02-10

VIKTORIA-1

Celcuity Inc

Phase 3 Active not recruiting
701 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡